Triple Leaf Bio-B (02197.HK) announced that in the Phase I clinical trial of SCB-1019, a bivalent RSVPreF-trimer subunit candidate vaccine developed based on the company's unique Trimer-Tag (protein trimerization) vaccine technology platform, positive preliminary immunogenicity and safety data were obtained in the elderly group (60 to 85 years old). These preliminary data obtained in the elderly group are consistent with the positive data obtained in the young adult group (18-59 years old) announced by the company in April of this year.
In the ongoing Phase I clinical trial, 48 subjects in the elderly group were enrolled and received either SCB1019 or normal saline placebo.